ArticleNucleic acids research2023
LncTarD 2.0: an updated comprehensive database for experimentally-supported functional lncRNA-target regulations in human diseases.
Article in Nucleic acids research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 71 citations in OpenAlex.
- Enhancing link prediction in biomedical knowledge graphs with BioPathNet.Nature biomedical engineering · 2026Article
- The LncRNA Expression Profile and Regulatory Network of Microsporidian During the Infection of Western Honeybee.Animals : an open access journal from MDPI · 2026Article
- Pan-cancer integrative profiling of immune-related lncRNAs unveils tumor microenvironment subtypes and prognostic biomarkers.Discover oncology · 2026Article
- Investigation of Long Non-Coding RNAsNon-coding RNA · 2026Article
- Identification and Characterization of Cancer-Related Risk Metabolic Subpathways Reveal Their Functional Significance in Cancer.International journal of molecular sciences · 2026Article
- Integrated spatial transcriptomics and pan-cancer XGBoost modeling uncover spatial drivers of immune exclusion and predict immunotherapy response.Cancer immunology, immunotherapy : CII · 2026Article
- Metamorphosis and lncRNAs: A Close Relationship.Genesis (New York, N.Y. : 2000) · 2026Review
- An in-depth transcriptomic atlas deciphering traditional Chinese medicine mechanisms and disease associations.Scientific data · 2026Article
- Whole genome circRNA profiling ofDrug metabolism and personalized therapy · 2026Article
- Comprehensive review of publicly accessible databases for gastrointestinal cancer and future challenges in database construction.Discover oncology · 2026Review
- So3D: a comprehensive three-dimensional spatial omics resource for decoding tissue architecture in physiology and disease.Nucleic acids research · 2026Article
- RegNetwork 2025: an integrative data repository for gene regulatory networks in human and mouse.Nucleic acids research · 2026Article
- LncRCD: A Comprehensive Database for Pan-Cancer Characterization of lncRNAs Related to 12 Regulated Cell Death Types.Computational and structural biotechnology journal · 2026Article
- HuRInterDB: A Database Exploring the Landscape of lncRNA-Protein Interactions.Computational and structural biotechnology journal · 2026Article
- Pivotal Role of miRNA-lncRNA Interactions in Human Diseases.Molecular biotechnology · 2025Review
- The role of long intergenic non-protein coding RNA 312 in cancer: A bioinformatics and literature based study.Biochemistry and biophysics reports · 2025Review
- Evaluation of Exosome-derived Small RNAs as Potential Biomarkers for Pancreatic Ductal Adenocarcinoma Using Next-generation Sequencing.Annals of laboratory medicine · 2025Article
- Deep learning algorithms reveal genomic markers for anxiety disorder in a large cohort of children with down syndrome.Molecular psychiatry · 2025Article
- A long noncoding RNA-based serum signature predicts ado-trastuzumab emtansine (T-DM1) treatment benefit in HER2+ metastatic breast cancer patients: a multicenter cohort study.Cell death discovery · 2025Article
- Severity-specific immune landscape of COVID-19 revealed by single-cell sequencing.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An updated LncTarD 2.0 database provides a comprehensive resource on key lncRNA-target regulations, their influenced functions and lncRNA-mediated regulatory mechanisms in human diseases. LncTarD 2.0 is freely available at (http://bio-bigdata.hrbmu.edu.cn/LncTarD or https://lnctard.bio-database.com/). LncTarD 2.0 was updated with several new features, including (i) an increased number of disease-associated lncRNA entries, where the current release provides 8360 key lncRNA-target regulations, with 419 disease subtypes and 1355 lncRNAs; (ii) predicted 3312 out of 8360 lncRNA-target regulations as potential diagnostic or therapeutic biomarkers in circulating tumor cells (CTCs); (iii) addition of 536 new, experimentally supported lncRNA-target regulations that modulate properties of cancer stem cells; (iv) addition of an experimentally supported clinical application section of 2894 lncRNA-target regulations for potential clinical application. Importantly, LncTarD 2.0 provides RNA-seq/microarray and single-cell web tools for customizable analysis and visualization of lncRNA-target regulations in diseases. RNA-seq/microarray web tool was used to mining lncRNA-target regulations in both disease tissue samples and CTCs blood samples. The single-cell web tools provide single-cell lncRNA-target annotation from the perspectives of pan-cancer analysis and cancer-specific analysis at the single-cell level. LncTarD 2.0 will be a useful resource and mining tool for the investigation of the functions and mechanisms of lncRNA deregulation in human disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.